Beyond CHAMPION-AF: Real-World Comparison of Cryoballoon and Pulsed Field Ablation for First-Time Pulmonary Vein Isolation

R. Wahedi (Hamburg)1, I. My (Hamburg)2, J. Dickow (Hamburg)1, T. Harloff (Hamburg)1, M. M. Ruhin (Hamburg)1, Z. G. Demirtakan (Hamburg)1, K. Massi (Hamburg)1, M. Maus (Hamburg)1, N. Geßler (Hamburg)1, J. M. Feldhege (Hamburg)1, M. Jularic (Hamburg)1, M. A. Gunawardene (Frankfurt am Main)3, J. Vogler (Hamburg)1, S. Willems (Hamburg)1, A. Sultan (Hamburg)1
1Asklepios Klinik St. Georg Kardiologie & internistische Intensivmedizin Hamburg, Deutschland; 2Universitäres Herz- und Gefäßzentrum Hamburg Klinik für Kardiologie Hamburg, Deutschland; 3Agaplesion Markus Krankenhaus Medizinische Klinik III - CCB Frankfurt am Main, Deutschland

Background:  Single-shot ablation technologies, mainly cryo-balloon (CB) and pulsed field ablation (PFA), are increasingly favored for first-time pulmonary vein isolation (PVI) due to their procedural efficiency and ability to achieve rapid, safe, and durable PVI. However, comparative data from large real-world cohorts remain limited.

Methods: Patients undergoing a first-time PVI at a German high-volume center between 2021 and 2025 were retrospectively analyzed. Baseline, acute safety, and readmission for re-PVI were systematically collected. A total of 1,961 patients were included, comprising 1,369 treated with CB and 592 with PFA using the penta-spline catheter.

Results: Baseline demographics were comparable between groups with respect to age (67 [59–74] vs. 67 [60–74] years, p = 0.72), sex (female 39% vs. 36%, p = 0.06), and AF type (persistent AF 53.9% vs. 54.4%, p = 0.88). The CB cohort demonstrated a higher prevalence of comorbidities including arterial hypertension (56.2% vs. 45.3%, p < 0.001), heart failure (6.4% vs. 2.9%, p < 0.001), diabetes mellitus (12.2% vs. 5.6%, p < 0.001), coronary artery disease (16.8% vs. 8.6%, p < 0.001) and peripheral artery disease (1.4% vs. 0.3%, p = 0.05)). Left ventricular ejection fraction, history of stroke/TIA, antiarrhythmic drug use, and anticoagulation rates were similar between groups. Acute overall complications occurred in 8.9% of CB and 3.7% of PFA procedures (p < 0.001). Major complication rates (death, tamponade, stroke/TIA, phrenic nerve injury, atrioesophageal fistula) did not differ significantly (0.8% vs. 0.5%, p = 0.6), whereas minor complications (vascular access, infection, acute kidney injury) were more frequent in the CB group (8.1% vs. 3.2%, p < 0.001). In multivariate regression analysis, higher age (OR 2.7, p = 0.007), female sex (OR 2.4, p = 0.017), and diabetes mellitus (OR 2.1, p = 0.036) independently predicted minor complications, while no variable predicted major events. During follow-up, patients were readmitted for re-PVI procedures in 169/1369 (12.3%) CB patients versus 35/592 (5.9%) PFA patients (p < 0.001). The data analysis of a structured clinical and holter ECG follow-up is currently ongoing.

Conclusion: In this large real-world cohort, both cryo-balloon and pulsed field ablation demonstrated high acute safety, but pulsed field ablation was associated with fewer minor complications and a reduced need for repeat procedures.